Engage Bio
Engage Bio is dedicated to unleashing DNA medicines through its innovative Tethosome platform, which offers highly potent, non-immunogenic, redosable, and scalable genetic therapies. The company's mission is to develop potent, durable, and safe genetic medicines that can be re-dosed and scaled efficiently, aiming to eliminate human diseases.
Industries
Nr. of Employees
small (1-50)
Engage Bio
Products
Tethosome platform (non-viral DNA delivery system)
A non-viral DNA delivery approach that co-delivers therapeutic DNA with an mRNA-encoded protein that tethers DNA to the nucleus to increase expression, reported to evade DNA-sensing immune pathways and enable durable, re-dosable expression.
Tethosome platform (non-viral DNA delivery system)
A non-viral DNA delivery approach that co-delivers therapeutic DNA with an mRNA-encoded protein that tethers DNA to the nucleus to increase expression, reported to evade DNA-sensing immune pathways and enable durable, re-dosable expression.
Services
Partnerships for therapeutic development
Collaborative development partnerships to apply the non-viral DNA platform across indications including gene replacement and oncology.
In vivo study execution and vivarium operations
Operational support and execution of in vivo studies, backed by in-house vivarium management experience.
Partnerships for therapeutic development
Collaborative development partnerships to apply the non-viral DNA platform across indications including gene replacement and oncology.
In vivo study execution and vivarium operations
Operational support and execution of in vivo studies, backed by in-house vivarium management experience.
Expertise Areas
- Non-viral gene delivery
- Lipid nanoparticle formulation and scale-up
- mRNA co-delivery strategies
- Nuclear localization strategies for enhanced expression
Key Technologies
- Non-viral DNA delivery platform
- Lipid nanoparticles (LNP)
- mRNA co-delivery
- Protein-mediated nuclear tethering